BRIEF—New UK HQ shows importance of British market to Celltrion

South Korean firm Celltrion has officially opened its new UK headquarters.

The Uxbridge facility was opened at a ceremony attended by Hyoung-Ki Kim, chief executive and vice chairman at Celltrion, Rosalind Campion, director of the Office for Life Sciences and Mark Samuels, chief executive of Medicines UK and the British Biosimilars Association.

This office will serve as Celltrion’s central hub for UK operations and places the firm among a growing list of life sciences companies including Regeneron, Amgen, Gilead Sciences and Daiichi Sankyo that have established presence in Uxbridge, to the west of London.

Celltrion has expanded its UK headcount by 20% over the past year and expects further recruitment and investment in the coming years.

Hyoung-Ki Kim said: “The opening our new UK office marks a pivotal milestone in Celltrion UK history. This demonstrates our strong commitment to the UK, a strategic market for our growth. We are here for the long term and are invested in the future of biosimilars in the UK. We look forward to continued collaboration with local institutions and regulatory bodies to ensure sustainable access to high-quality biologic treatments.”